Harbour BioMed Names Dr. Sanjay Keswani as Neuroscience Advisor
In a significant move to bolster its expertise in neuroscience, Harbour BioMed, a prominent global biopharmaceutical company, announced the appointment of Dr. Sanjay Keswani as its new Scientific Advisor in Neuroscience on November 17, 2026. Known for its commitment to developing groundbreaking antibody therapeutics across various fields, including immunology and oncology, Harbour BioMed continues to expand its leadership team with distinguished professionals from the industry.
Dr. Sanjay Keswani brings an impressive background with over 25 years of experience in neuroscience research, spanning various roles in both global pharmaceutical firms and biotechnology companies. His extensive knowledge covers multiple aspects of neuroscience, such as neurodegenerative diseases, neuroimmunology, rare disorders, and pain management. Moreover, he has a proven track record of successfully advancing innovative therapies from the initial stages of discovery through clinical development and onto regulatory approval.
Before taking on his new role at Harbour BioMed, Dr. Keswani served as Chief Medical Officer at Neurocrine Biosciences. In that capacity, he was responsible for overseeing clinical development processes across a wide range of therapeutic areas. His focus included neurology, psychiatry, immunology, obesity, and rare endocrine diseases. His extensive experience leading teams in drug development is expected to significantly benefit Harbour BioMed as it navigates the complex landscape of neuroscience.
Dr. Keswani’s career also includes serving as President and CEO of ImmunoBrain, a clinical-stage company dedicated to developing therapies aimed at enhancing neuro-immune communication to facilitate brain repairs in individuals suffering from neurodegenerative conditions. Additionally, he held the positions of Executive Vice President and Chief Medical Officer at Annexon Biosciences, where he directed clinical development efforts for several promising projects, including a positive Phase 2/3 clinical trial in Guillain-Barré syndrome and various Phase 2 studies in other critical areas such as Huntington's disease and amyotrophic lateral sclerosis (ALS).
Earlier in his career, he was Senior Vice President and Global Head of Neuroscience, Ophthalmology, and Rare Diseases at Roche, where he led a large team and was instrumental in progressing five drug candidates into Phase 3 clinical trials. Notably, his contributions include advancing treatments such as risdiplam (Evrysdi®) for spinal muscular atrophy and faricimab (Vabysmo®) for diabetic macular edema, showcasing his ability to translate scientific discoveries into viable treatment options.
Dr. Keswani’s journey in academia and research began at Johns Hopkins University where he worked as an Assistant Professor of Neurology. His research primarily focused on molecular neuroscience and neuroimmunology. Throughout his career, he has held senior roles in research and development at various leading companies including Bristol Myers Squibb, Eli Lilly, and Amgen, further solidifying his expertise in innovative therapy development.
Expressing his enthusiasm for joining Harbour BioMed, Dr. Keswani stated, “I am honored to join Harbour BioMed.” He emphasized the company’s robust foundation in antibody discovery and engineering, and how it has built a competitive product pipeline leveraging state-of-the-art technologies. He looks forward to contributing his vast experience in neuroscience and drug development to support the company's ongoing scientific efforts aimed at addressing significant unmet medical needs.
Dr. Jingsong Wang, the Founder, Chairman, and CEO of Harbour BioMed, welcomed Dr. Keswani saying, “We are delighted to have Dr. Keswani join us. His extensive knowledge in neuroscience research and drug development will provide invaluable insights as we continue to advance innovative therapies in the neuroscience sector.”
As Harbour BioMed continues to leverage its proprietary antibody technology platform, Harbour Mice®, and its various advanced methodologies such as HBICE® for immune cell engagers, the company is poised to create a pipeline of innovative therapies aimed at improving patient outcomes in the area of neuroscience and beyond.
For more detailed information on Harbour BioMed and its ongoing projects, you can visit their official website at
www.harbourbiomed.com.